Synfini, Inc., the leader in AI-driven agile chemistry for better molecule discovery, announced today that it has entered a collaboration with biotechnology company Multispan to co-discover and develop drug candidates against an undisclosed G protein-coupled receptor (GPCR) target. The collaboration will combine Multspan’s world-leading expertise in GPCR biology and assay capabilities with the Synfini AI Cloud Foundry that accelerates drug discovery through AI and chemistry automation. 

"We are excited to be entering into this collaboration with Synfini to accelerate drug discovery around a publicly available high-value target,” said Helena Mancebo, CEO of Multispan. "By using Synfini’s AI design and rapid chemistry automation tools we have already achieved our first milestones in the collaboration.” 

The Synfini Cloud Foundry accelerates “design-make -test-analyze” (DMTA) cycles in molecular discovery by automating workflows in virtual design and physical experiment. Drug hunters can perform complex multi-parametric optimization from their desktops to drive small molecule hit discovery, hit-to-lead and lead optimization. This approach to agile drug discovery identifies better preclinical drug candidates faster and more cost-effectively. 

"We are very pleased to work with Multispan on a challenging target that addresses significant unmet medical need for patients,” said Doug Donzelli, CEO of Synfini. “Multispan brings the best assays available to improve GPCR drug discovery that, when combined with the Synfini platform, can drive significant reductions in discovery cycle times. Through the partnership, both Synfini and Multispan customers will benefit from the foundational drug discovery assets we provide." 

The two companies have further agreed to make their combined technology platforms commercially available to the drug discovery community specializing in GPCR and other targets. By doing so Synfini and Multispan will provide a “one stop shop” for accelerated drug discovery using AI, automation and cutting-edge biology for clients and partners with their own targets. Drug candidates resulting from the current target collaboration will also be available to customers looking for advanced preclinical assets for clinical development.